In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: Application of the mechanistic absorption model GI-Sim

European Journal of Pharmaceutical Sciences

Volumn 49, Issue 4, 2013, Pages 679-698

  Sjögren, Erik ^a   Westergren, Jan ^b   Grant, Iain ^c   Hanisch, Gunilla ^d   Lindfors, Lennart ^d   Lennernäs, Hans ^a   Abrahamsson, Bertil ^d   Tannergren, Christer ^d  

^a UPPSALA UNIVERSITY   (Sweden)

^b Wendelsbergs beräkningskemi AB   (Sweden)

^c ASTRAZENECA   (United Kingdom)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

Absorption modeling; Fraction absorbed; In silico prediction; Intestinal permeability; Solubility

Indexed keywords

APREPITANT; BUFFER; CARBAMAZEPINE; DANAZOL; DIGOXIN; FELODIPINE; FENOFIBRATE; FEXOFENADINE; GASTROINTESTINAL AGENT; GRISEOFULVIN; IRBESARTAN; KETOCONAZOLE; NALOXEGOL; SODIUM CHLORIDE; TESAGLITAZAR;

ALGORITHM; AREA UNDER THE CURVE; ARTICLE; COMPUTER MODEL; DECISION MAKING; DISSOLUTION; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; EXPOSURE; GASTROINTESTINAL ABSORPTION; HYPERTENSION; INTESTINE FLUID; MICELLE; MOLECULAR WEIGHT; PARTICLE SIZE; PERMEABILITY; PHYSICOCHEMICAL MODEL; PLASMA; PLASMA CONCENTRATION-TIME CURVE; PRECIPITATION; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 84879468832     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.05.019     Document Type: Article

References (101)

1. Aapro, M.S., Walko, C.M., 2010. Aprepitant: drug-drug interactions in perspective. Ann. Oncol. 21, 2316-2323.
2. Agoram, B., Woltosz, W.S., Bolger, M.B., 2001. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv. Drug Deliv. Rev. 50 (Suppl 1), S41-67. (Pubitemid 32905355)
3. Amidon, G.L., Lennernäs, H., Shah, V.P., Crison, J.R., 1995. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12, 413-420.
4. Avdeef, A., Tam, K.Y., 2010. How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability? J. Med. Chem. 53, 3566-3584.
5. Baarnhielm, C., Backman, A., Hoffmann, K.J., Weidolf, L., 1986. Biotransformation of felodipine in liver microsomes from rat, dog, and man. Drug Metab. Dispos. 14, 613-618. (Pubitemid 16026726)
6. Badcock, N.R., Bartholomeusz, F.D., Frewin, D.B., Sansom, L.N., Reid, J.G., 1987. The pharmacokinetics of ketoconazole after chronic administration in adults. Eur. J. Clin. Pharmacol. 33, 531-534. (Pubitemid 18017558)
7. Benet, L., Wu, C., Custodio, J., 2006. Predicting drug absorption and the effects of food on oral bioavailability. Bull. Techn. Gattefosse, 9-16.
8. Benet, L.Z., Cummins, C.L., 2001. The drug efflux-metabolism alliance: biochemical aspects. Adv. Drug Deliv. Rev. 50 (Suppl. 1), S3-11.
9. Borgström, L., Nyberg, L., Jonsson, S., Lindberg, C., Paulson, J., 1989. Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate. Br. J. Clin. Pharmacol. 27, 49-56. (Pubitemid 19037979)
10. Brandsch, M., Knütter, I., Bosse-Doenecke, E., 2008. Pharmaceutical and pharmacological importance of peptide transporters. J. Pharm. Pharmacol. 60, 543-585. (Pubitemid 351589044)
11. Cagigal, E., Gonzalez, L., Alonso, R.M., Jimenez, R.M., 2001. PK(a) determination of angiotensin II receptor antagonists (ARA II) by spectrofluorimetry. J. Pharm. Biomed. Anal. 26, 477-486. (Pubitemid 32727666)
12. Carlert, S., Pålsson, A., Hanisch, G., von Corswant, C., Nilsson, C., Lindfors, L., Lennernäs, H., Abrahamsson, B., 2010. Predicting intestinal precipitation - a case example for a basic BCS class II drug. Pharm. Res. 27, 2119-2130.
13. Chando, T.J., Everett, D.W., Kahle, A.D., Starrett, A.M., Vachharajani, N., Shyu, W.C., Kripalani, K.J., Barbhaiya, R.H., 1998. Biotransformation of irbesartan in man. Drug Metab. Dispos. 26, 408-417. (Pubitemid 28223881)
14. Charman, W.N., Rogge, M.C., Boddy, A.W., Berger, B.M., 1993. Effect of food and a monoglyceride emulsion formulation on danazol bioavailability. J. Clin. Pharmacol. 33, 381-386. (Pubitemid 23141537)
15. Chiou, W.L., Chung, S.M., Wu, T.C., Ma, C., 2001. A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. Int. J. Clin. Pharmacol. Ther. 39, 93-101. (Pubitemid 32208536)
16. Chiou, W.L., Riegelman, S., 1971. Absorption characteristics of solid dispersed and micronized griseofulvin in man. J. Pharm. Sci. 60, 1376-1380.
17. Daneshmend, T.K., Warnock, D.W., Ene, M.D., Johnson, E.M., Potten, M.R., Richardson, M.D., Williamson, P.J., 1984. Influence of food on the pharmacokinetics of ketoconazole. Antimicrob. Agents Chemother. 25, 1-3. (Pubitemid 14223534)
18. Darwich, A.S., Neuhoff, S., Jamei, M., Rostami-Hodjegan, A., 2010. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model. Curr. Drug Metab. 11, 716-729.
19. Edgar, B., Regårdh, C.G., Johnsson, G., Johansson, L., Lundborg, P., Löfberg, I., Rönn, O., 1985. Felodipine kinetics in healthy men. Clin. Pharmacol. Ther. 38, 205-211. (Pubitemid 16248174)
20. Edwards, F., Tsakmaka, C., Mohr, S., Fielden, P.R., Goddard, N.J., Booth, J., Tam, K.Y., 2013. Using droplet-based microfluidic technology to study the precipitation of a poorly water-soluble weakly basic drug upon a pH-shift. Analyst 138, 339-345.
21. Fagerholm, U., Lennernäs, H., 1995. Experimental estimation of the effective unstirred water layer thickness in the human jejunum, and its importance in oral-drug absorption. Eur. J. Pharm. Sci. 3, 247-253.
22. Fenner, K.S., Troutman, M.D., Kempshall, S., Cook, J.A., Ware, J.A., Smith, D.A., Lee, C.A., 2009. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin. Pharmacol. Ther. 85, 173-181.
23. Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H.P., von Richter, O., Zundler, J., Kroemer, H.K., 1999. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104, 147-153.
24. Hayeshi, R., Hilgendorf, C., Artursson, P., Augustijns, P., Brodin, B., Dehertogh, P., Fisher, K., Fossati, L., Hovenkamp, E., Korjamo, T., Masungi, C., Maubon, N., Mols, R., Müllertz, A., Monkkonen, J., O'Driscoll, C., Oppers-Tiemissen, H.M., Ragnarsson, E.G., Rooseboom, M., Ungell, A.L., 2008. Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. Eur. J. Pharm. Sci. 35, 383-396.
25. Heikkinen, A.T., Baneyx, G., Caruso, A., Parrott, N., 2012. Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates - an evaluation and case study using GastroPlus. Eur. J. Pharm. Sci. 47, 375-386.
26. Hellriegel, E.T., Bjornsson, T.D., Hauck, W.W., 1996. Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin. Pharmacol. Ther. 60, 601-607. (Pubitemid 27025907)
27. Henderson, L.J., 1908. Concerning the relationship between the strength of acids and their capacity to preserve neutrality. Am. J. Physiol. 21, 173-179.
28. Hogben, C.A., Tocco, D.J., Brodie, B.B., Schanker, L.S., 1959. On the mechanism of intestinal absorption of drugs. J. Pharmacol. Exp. Ther. 125, 275-282.
29. Hooper, W.D., Eadie, M.J., Dickinson, R.G., 1991. Single oral dose pharmacokinetics and comparative bioavailability of danazol in humans. Biopharm. Drug Dispos. 12, 577-582.
30. Huang, Y.C., Colaizzi, J.L., Bierman, R.H., Woestenborghs, R., Heykants, J., 1986. Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. Antimicrob. Agents Chemother. 30, 206-210. (Pubitemid 16038748)
31. Igel, S., Drescher, S., Murdter, T., Hofmann, U., Heinkele, G., Tegude, H., Glaeser, H., Brenner, S.S., Somogyi, A.A., Omari, T., Schäfer, C., Eichelbaum, M., Fromm, M.F., 2007. Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux. Clin. Pharmacokinet. 46, 777-785. (Pubitemid 47347449)
32. Jalava, K.M., Olkkola, K.T., Neuvonen, P.J., 1997. Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin. Pharmacol. Ther. 61, 410-415. (Pubitemid 27195943)
33. Jiang, W., Kim, S., Zhang, X., Lionberger, R.A., Davit, B.M., Conner, D.P., Yu, L.X., 2011. The role of predictive biopharmaceutical modeling and simulation in drug development and regulatory evaluation. Int. J. Pharm. 418, 151-160.
34. Jones, H.M., Gardner, I.B., Collard, W.T., Stanley, P.J., Oxley, P., Hosea, N.A., Plowchalk, D., Gernhardt, S., Lin, J., Dickins, M., Rahavendran, S.R., Jones, B.C., Watson, K.J., Pertinez, H., Kumar, V., Cole, S., 2011. Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling. Clin. Pharmacokinet. 50, 331-347.
35. Jounela, A.J., Pentikainen, P.J., Sothmann, A., 1975. Effect of particle size on the bioavailability of digoxin. Eur. J. Clin. Pharmacol. 8, 365-370.
36. Jönsson, S., Henningsson, A., Edholm, M., Salmonson, T., 2012. Role of modelling and simulation: a European regulatory perspective. Clin. Pharmacokinet. 51, 69-76.
37. Kansy, M., Senner, F., Gubernator, K., 1998. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J. Med. Chem. 41, 1007-1010. (Pubitemid 28207375)
38. Karlsson, J., Artursson, P., 1991. A method for the determination of cellular permeability coefficients and aqueous boundary-layer thickness in monolayers of intestinal epithelial (Caco-2) cells grown in permeable filter chambers. Int. J. Pharm. 71, 55-64.
39. Kerr, B.M., Thummel, K.E., Wurden, C.J., Klein, S.M., Kroetz, D.L., Gonzalez, F.J., Levy, R.H., 1994. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem. Pharmacol. 47, 1969-1979.
40. Kesisoglou, F., Wu, Y., 2008. Understanding the effect of API properties on bioavailability through absorption modeling. AAPS J. 10, 516-525.
41. Konishi, H., Takenaka, A., Minouchi, T., Yamaji, A., 2001. Impairment of CYP3A4 capacity in patients receiving danazol therapy: examination on oxidative cortisol metabolism. Horm. Metab. Res. 33, 628-630. (Pubitemid 33015968)
42. Kotlarchyk, M., Stephens, R.B., Huang, J.S., 1988. Study of Schultz distribution to model polydispersity of microemulsion droplets. J. Phys. Chem. - US 92, 1533-1538.
43. Kovacevic, I., Parojcic, J., Homsek, I., Tubic-Grozdanis, M., Langguth, P., 2009. Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation. Mol. Pharm. 6, 40-47.
44. Lancaster, S.G., Todd, P.A., 1988. Lisinopril. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 35, 646-669.
45. Lappin, G., Shishikura, Y., Jochemsen, R., Weaver, R.J., Gesson, C., Houston, B., Oosterhuis, B., Bjerrum, O.J., Rowland, M., Garner, C., 2010. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. Eur. J. Pharm. Sci. 40, 125-131.
46. Lennernäs, H., 2007. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica 37, 1015-1051. (Pubitemid 350035536)
47. Lin, C., Symchowicz, S., 1975. Absorption, distribution, metabolism, and excretion of griseofulvin in man and animals. Drug Metab. Rev. 4, 75-95.
48. Lin, C.C., Magat, J., Chang, R., McGlotten, J., Symchowicz, S., 1973. Absorption, metabolism and excretion of 14C-griseofulvin in man. J. Pharmacol. Exp. Ther. 187, 415-422.
49. Lindfors, L., Forssen, S., Westergren, J., Olsson, U., 2008. Nucleation and crystal growth in supersaturated solutions of a model drug. J. Colloid Interface Sci. 325, 404-413.
50. Löbenberg, R., Amidon, G.L., 2000. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur. J. Pharm. Biopharm. 50, 3-12. (Pubitemid 30326685)
51. Majumdar, A.K., Howard, L., Goldberg, M.R., Hickey, L., Constanzer, M., Rothenberg, P.L., Crumley, T.M., Panebianco, D., Bradstreet, T.E., Bergman, A.J., Waldman, S.A., Greenberg, H.E., Butler, K., Knops, A., De Lepeleire, I., Michiels, N., Petty, K.J., 2006. Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J. Clin. Pharmacol. 46, 291-300. (Pubitemid 43260316)
52. Marino, M.R., Langenbacher, K., Ford, N.F., Uderman, H.D., 1998. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects. J. Clin. Pharmacol. 38, 246-255. (Pubitemid 28144930)
53. Martin, F.H., Tsuk, A.G., 1982. Therapeutic Compositions with Enhanced Bioavailability. American Home Products Corporation, US, New York.
54. Marvel, J.R., Schlichting, D.A., Denton, C., Levy, E.J., Cahn, M.M., 1964. The effect of a surfactant and of particle size on griseofulvin plasma levels. J. Invest. Dermatol. 42, 197-203.
55. Mazer, N.A., Benedek, G.B., Carey, M.C., 1980. Quasielastic light-scattering studies of aqueous biliary lipid systems. Mixed micelle formation in bile salt-lecithin solutions. Biochemistry 19, 601-615.
56. Ming, X., Knight, B.M., Thakker, D.R., 2011. Vectorial transport of fexofenadine across Caco-2 cells: involvement of apical uptake and basolateral efflux transporters. Mol. Pharm. 8, 1677-1686.
57. Mudie, D.M., Amidon, G.L., Amidon, G.E., 2010. Physiological parameters for oral delivery and in vitro testing. Mol. Pharm.
58. Müllertz, A., Fatouros, D.G., Smith, J.R., Vertzoni, M., Reppas, C., 2012. Insights into intermediate phases of human intestinal fluids visualized by atomic force microscopy and cryo-transmission electron microscopy ex vivo. Mol. Pharmaceut. 9, 237-247.
59. Nawroth, T., Buch, P., Buch, K., Langguth, P., Schweins, R., 2011. Liposome formation from bile salt-lipid micelles in the digestion and drug delivery model FaSSIF(mod) estimated by combined time-resolved neutron and dynamic light scattering. Mol. Pharm. 8, 2162-2172.
60. Nielsen, A.E., 1961. Diffusion controlled growth of a moving sphere. The kinetics of crystal growth in potassium perchlorate precipitation. J. Phys. Chem. 65, 46-49.
61. Ochs, H.R., Bodem, G., Greenblatt, D.J., 1981. Effect of dose on bioavailability of oral digoxin. Eur. J. Clin. Pharmacol. 19, 53-55. (Pubitemid 11197407)
62. Ochs, H.R., Greenblatt, D.J., Bodem, G., Harmatz, J.S., 1978. Dose-independent pharmacokinetics of digoxin in humans. Am. Heart J. 96, 507-511. (Pubitemid 9026129)
63. Otte, A., Carvajal, M.T., 2011. Assessment of milling-induced disorder of two pharmaceutical compounds. J. Pharm. Sci. 100, 1793-1804.
64. Pang, K.S., 2003. Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series). Drug Metab. Dispos. 31, 1507-1519. (Pubitemid 37466919)
65. Parrott, N., Lave, T., 2008. Applications of physiologically based absorption models in drug discovery and development. Mol. Pharm. 5, 760-775.
66. Parrott, N., Lukacova, V., Fraczkiewicz, G., Bolger, M.B., 2009. Predicting pharmacokinetics of drugs using physiologically based modeling - application to food effects. AAPS J. 11, 45-53.
67. Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J., Raunio, H., 2008. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch. Toxicol. 82, 667-715.
68. Persson, E.M., Gustafsson, A.S., Carlsson, A.S., Nilsson, R.G., Knutson, L., Forsell, P., Hanisch, G., Lennernäs, H., Abrahamsson, B., 2005. The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids. Pharm. Res. 22, 2141-2151. (Pubitemid 41821594)
69. Petri, N., Borga, O., Nyberg, L., Hedeland, M., Bondesson, U., Lennernäs, H., 2006. Effect of erythromycin on the absorption of fexofenadine in the jejunum, ileum and colon determined using local intubation in healthy volunteers. Int. J. Clin. Pharmacol. Ther. 44, 71-79. (Pubitemid 43230589)
70. Petri, N., Tannergren, C., Rungstad, D., Lennernäs, H., 2004. Transport characteristics of fexofenadine in the Caco-2 cell model. Pharm. Res. 21, 1398-1404. (Pubitemid 39149654)
71. Poulin, P., Jones, R.D., Jones, H.M., Gibson, C.R., Rowland, M., Chien, J.Y., Ring, B.J., Adkison, K.K., Ku, M.S., He, H., Vuppugalla, R., Marathe, P., Fischer, V., Dutta, S., Sinha, V.K., Bjornsson, T., Lave, T., Yates, J.W., 2011. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. J. Pharm. Sci.
72. Psachoulias, D., Vertzoni, M., Goumas, K., Kalioras, V., Beato, S., Butler, J., Reppas, C., 2011. Precipitation in and supersaturation of contents of the upper small intestine after administration of two weak bases to fasted adults. Pharm. Res. 28, 3145-3158.
73. Robbins, D.K., Castles, M.A., Pack, D.J., Bhargava, V.O., Weir, S.J., 1998. Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers. Biopharm. Drug Dispos. 19, 455-463. (Pubitemid 28474562)
74. Sanchez, R.I., Wang, R.W., Newton, D.J., Bakhtiar, R., Lu, P., Chiu, S.H., Evans, D.C., Huskey, S.E., 2004. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab. Dispos. 32, 1287-1292. (Pubitemid 39410914)
75. Sauron, R., Wilkins, M., Jessent, V., Dubois, A., Maillot, C., Weil, A., 2006. Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation. Int. J. Clin. Pharmacol. Ther. 44, 64-70. (Pubitemid 43230588)
76. Schiller, C., Frohlich, C.P., Giessmann, T., Siegmund, W., Monnikes, H., Hosten, N., Weitschies, W., 2005. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment. Pharm. Therap. 22, 971-979. (Pubitemid 41634879)
77. Shimizu, M., Fuse, K., Okudaira, K., Nishigaki, R., Maeda, K., Kusuhara, H., Sugiyama, Y., 2005. Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab. Dispos. 33, 1477-1481. (Pubitemid 41323995)
78. Skiba, M., Skiba-Lahiani, M., Marchais, H., Duclos, R., Arnaud, P., 2000. Stability assessment of ketoconazole in aqueous formulations. Int. J. Pharm. 198, 1-6. (Pubitemid 30155545)
79. Straughn, A.B., Meyer, M.C., Raghow, G., Rotenberg, K., 1980. Bioavailability of microsize and ultramicrosize griseofulvin products in man. J. Pharmacokinet. Biopharm. 8, 347-362. (Pubitemid 10025208)
80. Sugano, K., 2009. Introduction to computational oral absorption simulation. Expert Opin. Drug Metab. Toxicol. 5, 259-293.
81. Sugano, K., 2011. Fraction of a dose absorbed estimation for structurally diverse low solubility compounds. Int. J. Pharm. 405, 79-89.
82. Sunesen, V.H., Vedelsdal, R., Kristensen, H.G., Christrup, L., Müllertz, A., 2005. Effect of liquid volume and food intake on the absolute bioavailability of danazol, a poorly soluble drug. Eur. J. Pharm. Sci. 24, 297-303. (Pubitemid 40283512)
83. Söderlind, E., Karlsson, E., Carlsson, A., Kong, R., Lenz, A., Lindborg, S., Sheng, J.J., 2010. Simulating fasted human intestinal fluids: understanding the roles of lecithin and bile acids. Mol. Pharm.
84. Takano, R., Furumoto, K., Shiraki, K., Takata, N., Hayashi, Y., Aso, Y., Yamashita, S., 2008. Rate-limiting steps of oral absorption for poorly water-soluble drugs in dogs; prediction from a miniscale dissolution test and a physiologically-based computer simulation. Pharm. Res. 25, 2334-2344.
85. Tannergren, C., Bergendal, A., Lennernäs, H., Abrahamsson, B., 2009. Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment. Mol. Pharm. 6, 60-73.
86. Tannergren, C., Knutson, T., Knutson, L., Lennernäs, H., 2003. The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. Br. J. Clin. Pharmacol. 55, 182-190. (Pubitemid 36237864)
87. Thelen, K., Coboeken, K., Willmann, S., Burghaus, R., Dressman, J.B., Lippert, J., 2011. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: oral solutions. J. Pharm. Sci. - US 100, 5324-5345.
88. Uno, T., Shimizu, M., Sugawara, K., Tateishi, T., 2006. Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. Drug Metab. Dispos. 34, 1875-1879. (Pubitemid 44771716)
89. Vachharajani, N.N., Shyu, W.C., Chando, T.J., Everett, D.W., Greene, D.S., Barbhaiya, R.H., 1998. Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers. J. Clin. Pharmacol. 38, 702-707. (Pubitemid 28388219)
90. Weil, A., Caldwell, J., Strolin-Benedetti, M., 1990. The metabolism and disposition of 14C-fenofibrate in human volunteers. Drug Metab. Dispos. 18, 115-120. (Pubitemid 20085660)
91. Willmann, S., Schmitt, W., Keldenich, J., Lippert, J., Dressman, J.B., 2004. A physiological model for the estimation of the fraction dose absorbed in humans. J. Med. Chem. 47, 4022-4031. (Pubitemid 38970963)
92. Vogt, M., Kunath, K., Dressman, J.B., 2008. Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: comparison with commercial preparations. Eur. J. Pharm. Biopharm. 68, 283-288.
93. Wu, Y., Loper, A., Landis, E., Hettrick, L., Novak, L., Lynn, K., Chen, C., Thompson, K., Higgins, R., Batra, U., Shelukar, S., Kwei, G., Storey, D., 2004. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int. J. Pharm. 285, 135-146. (Pubitemid 39361543)
94. Yasui-Furukori, N., Uno, T., Sugawara, K., Tateishi, T., 2005. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin. Pharmacol. Ther. 77, 17-23. (Pubitemid 40075385)
95. Yu, L.X., Amidon, G.L., 1998. Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data. Eur. J. Pharm. Biopharm. 45, 199-203. (Pubitemid 28167747)
96. Yu, L.X., Amidon, G.L., 1999. A compartmental absorption and transit model for estimating oral drug absorption. Int. J. Pharm. 186, 119-125. (Pubitemid 29459038)
97. Yu, L.X., Crison, J.R., Amidon, G.L., 1996. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int. J. Pharm. 140, 111-118. (Pubitemid 26276720)
98. Zhang, X., Lionberger, R.A., Davit, B.M., Yu, L.X., 2011. Utility of physiologically based absorption modeling in implementing quality by design in drug development. AAPS J. 13, 59-71.
99. Zhao, P., Rowland, M., Huang, S.M., 2012. Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions. Clin. Pharmacol. Ther. 92, 17-20.
100. Zhu, T., Ansquer, J.C., Kelly, M.T., Sleep, D.J., Pradhan, R.S., 2010. Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans. J. Clin. Pharmacol. 50, 914-921.
101. Zimm, B.H., 1948. Apparatus and methods for measurement and interpretation of the angular variation of light scattering - preliminary results on polystyrene solutions. J. Chem. Phys. 16, 1099-1116.